You just read:

Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors

News provided by

Mirati Therapeutics, Inc.

Nov 08, 2018, 16:32 ET